|Description:||1. Ganoderic acid B has antinociceptive effect.|
2. Ganoderic acid B is a chemical marker in quality control of G. lucidum and related products.
3. Ganoderic acid B-containing herbs has potential influence towards therapeutic window of trifluoperazine.
4. Ganoderic acid B is moderately active inhibitors against HIV-1 protease with a 50% inhibitory concentration of 0.17-0.23 mM.
|Targets:||JAK | STAT | IL Receptor | p38MAPK | NF-kB|
|Source:||The fruit body of Ganoderma lucidum|
|Solvent:||Chloroform, Dichloromethane, Ethyl Acetate, DMSO, Acetone, etc.|
|Storage:||Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 24 months(2-8C).
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Need more advice on solubility, usage and handling? Please email to: firstname.lastname@example.org
|After receiving:||The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.|
|1 mg||5 mg||10 mg||20 mg||25 mg|
|1 mM||1.9354 mL||9.6768 mL||19.3536 mL||38.7072 mL||48.384 mL|
|5 mM||0.3871 mL||1.9354 mL||3.8707 mL||7.7414 mL||9.6768 mL|
|10 mM||0.1935 mL||0.9677 mL||1.9354 mL||3.8707 mL||4.8384 mL|
|50 mM||0.0387 mL||0.1935 mL||0.3871 mL||0.7741 mL||0.9677 mL|
|100 mM||0.0194 mL||0.0968 mL||0.1935 mL||0.3871 mL||0.4838 mL|
Biomed Chromatogr. 2013 Sep;27(9):1177-87.
|Structural identification of the metabolites of ganoderic acid B from Ganoderma lucidum in rats based on liquid chromatography coupled with electrospray ionization hybrid ion trap and time-of-flight mass spectrometry.[Pubmed: 23723086]|
|Ganoderic acid B (GAB), a representative triterpenoid in Ganoderma lucidum, possesses various pharmaceutical effects and has been used as a chemical marker in quality control of G. lucidum and related products. The metabolites of Ganoderic acid B in vivo after its oral administration to rats were investigated by liquid chromatography coupled with electrospray ionization hybrid ion trap and time-of-flight mass spectrometry. A total of 14 metabolites of Ganoderic acid B in rat plasma, bile and various organs were detected and identified by direct comparison with the authentic compounds and their characteristic mass fragmentation patterns. The results showed that oxidization and hydroxylation were the common metabolic pathways for Ganoderic acid B in rats. Moreover, some reduction metabolites of Ganoderic acid B were detected in rat kidney and stomach and glucuronidation only appeared in rat bile. This is the first report on the metabolites of Ganoderic acid B in vivo.|
Afr Health Sci. 2015 Mar;15(1):146-9.
|Ganoderic acid B's influence towards the therapeutic window of trifluoperazine (TFP).[Pubmed: 25834543]|
|BACKGROUND: Ganoderic acid B is an important bioactive ingredient isolated from Ganoderma lucidum, and exhibits various pharmacological activities. AIMS: To investigate the influence of Ganoderic acid B towards the therapeutic window of trifluoperazine (TFP). METHODS: In vitro human liver microsomes (HLMs) incubation system was used to determine the inhibition of Ganoderic acid B towards the glucuronidation of trifluoperazine (TFP). RESULTS: Ganoderic acid B exerted concentration-dependent inhibition towards the glucuronidation of TFP. Furthermore, Dixon plot was used to determine the inhibition type. The intersection point was located in the second quadrant in Dixon plot, indicating the competitive inhibition of Ganoderic acid B towards TFP glucuronidation. Through fitting the data using competitive nonlinear fitting equation, the inhibition kinetic parameter was calculated to be 56.7 uM. CONCLUSION: All this data indicated the potential influence of Ganoderic acid B-containing herbs towards therapeutic window of TFP. Given that the glucuronidation reaction of TFP is the probe reaction of UGT1A4, the data obtained from the present study also indicated the potential influence of Ganoderic acid-containing herbs towards the therapeutic window of drugs mainly undergoing UGT1A4-mediated metabolism.|